

Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

NCT07357051

Status	RECRUITING
Phase	Phase 3
Sponsor	Joincare Pharmaceutical Group Industry Co., Ltd
Enrollment	177 participants

Key Eligibility Criteria

Inclusion (6)

- Pediatric patients within the specified age range.
- Clinical presentation consistent with influenza, confirmed by a positive local rapid test or central laboratory PCR test.
- Presentation for treatment within the early symptomatic phase of influenza illness.
- Presence of fever and at least one respiratory symptom.
- Ability to swallow oral suspension.
- ... and 1 more (see full listing online)

Exclusion (8)

- Clinical signs suggestive of severe or complicated influenza infection
- requiring inpatient management.
- Presence of a concurrent bacterial infection requiring systemic therapy.
- Significant immunocompromised, or severe/uncontrolled comorbid conditions.
- History of hypersensitivity to any component of the investigational products.
- ... and 3 more (see full listing online)

Locations (1 total)

First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China